YL202
Phase 3Small molecule
YL202 is one of 98 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 3.
4
Indications
7
Total Trials
7
Active Trials
97
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1YL202
MMediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
Voltaren
NovartisPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Tricor
JJagotec
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Rilvegostomig
AstraZenecaPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors3 trials
Non-Small Cell Lung Cancer2 trials
Breast Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YL202. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details